An assessment of antioxidant status in patients with carbon monoxide poisoning

doi:10.5847/wjem.j.issn.1920-8642.2014.02.002

Abstract

Abstract:

BACKGROUND: Carbon monoxide poisoning (COP) is an important cause of mortality and morbidity worldwide. This study was to investigate the levels of serum paraoxonase (PON), arylesterase (ARYL), ceruloplasmin (Cp), and sulfhydryl (-SH) in the treatment of COP, and to further understand the pathophysiology of COP.
METHODS: This prospective study comprised 107 individuals with COP (group 1) and 50 healthy volunteers (group 2). Serum, plasma, and erythrocyte samples were taken on admission from all participants with COP. This process was repeated in the 90^th and 180^th minutes of treatment. Samples were taken from the control group only once. The levels of plasma PON, ARYL, Cp activity and -SH were measured in both groups.
RESULTS: Age, gender, and carboxyhemoglobin level were not correlated with PON, ARYL, Cp, and -SH levels. PON, ARYL, and -SH levels were significantly decreased in group 1 compared with group 2. Conversely, Cp was significantly elevated in group 1 in contrast to group 2. Although ARYL was lower on admission in patients with COP than that was observed in the 90^th and 180^th minutes (P<0.001), Cp was higher on admission than at the other time points (P<0.001).
CONCLUSIONS: Participants with COP had decreased levels of antioxidants (PON, ARLY, and -SH). COP represses the antioxidant system.

Key words: Carbon monoxide poisoning, Paraoxonase, Arylesterase, Ceruloplasmin, Total sulfhydryl groups

Suat Zengin, Behcet A, Sahin Karta, Basri Can, Mustafa Orkmez, Abdullah Taskın, Ugur Lok, Bediha Gulen, Cuma Yildirim, Seyithan Taysi. An assessment of antioxidant status in patients with carbon monoxide poisoning[J]. World Journal of Emergency Medicine, 2014, 5(2): 91-95.

Figures/Tables 3

Table 1

Table 2

Table 3

References 29

1	Weaver LK. Clinical practice. Carbon monoxide poisoning. N Engl J Med 2009; 360:1217-1725. doi: 10.1056/NEJMcp0808891 pmid: 19297574
2	Kao LW, Nanagas KA. Carbon monoxide poisoning. Emerg Med Clin N Am 2004; 22:985-1018.
3	Centers for Disease Control and Prevention. Carbon monoxide related deaths United States, 1999-2004, Morbidity and Mortality Weekly Report, December 21, 2007. MMWR Morb Mortal Wkly Rep 2007; 56:1309-1312. pmid: 18097342
4	Al B, Yildirim C, Zengin S, Cavdar M, Togun I. The effect of chronic carbon-monoxide exposure on the peak expiratory flow values of grill-kebab chefs. Saudi Med J 2009; 30:788-792. pmid: 19526161
5	Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 2007; 39:44-84. doi: 10.1016/j.biocel.2006.07.001 pmid: 16978905
6	Karakaya A, İbiş S, Kural T, Köse SK, Karakaya AE. Serum paraoxonase activity and phenotype distribution in Turkish subjects with coronary heart disease and its relationship to serum lipids and lipoproteins. Chem Biol Interact 1999; 118:193-200. pmid: 10362226
7	Aslan M, Kosecik M, Horoz M, Selek S, Celik H, Erel O. Assessment of paraoxonase and arylesterase activities in patients with iron deficiency anemia. Atherosclerosis 2007; 191:397-402. doi: 10.1016/j.atherosclerosis.2006.04.007 pmid: 16684543
8	Canales A, Sanchez-Muniz FJ. Paraoxanase, something more than an enzyme? Med Clin (Barc) 2003; 121:537-548.
9	Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BNJ. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: A possible peroxidative role for paraoxonase. J Clin Invest 1998; 101:1581-1590.
10	Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, et al. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low-densitylipoprotein. J Clin Invest 1995; 96:2882-2891. doi: 10.1172/JCI118359 pmid: 8675659
11	Horoz M, Aslan M, Selek S, Koylu AO, Bolukbas C, Bolukbas FF, et al. PON1 status in haemodialysis patients and the impact of hepatitis C infection. Clin Biochem 2007; 40:609-614. doi: 10.1016/j.clinbiochem.2007.01.019 pmid: 17335792
12	Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 1983; 35:1126-1138. pmid: 6316781
13	Baskol G, Baskol M, Kocer D. Oxidative stress and antioxidant defense in serum of patients with non-alcoholic steatohepatitis. Clin Biochem 2007; 40:776-780.
14	Meritxell NM, Francisco JSM, Jose VSG, Elvira LO, Jose MSM. Determination of rat and mice arylesterase activity using serum mimetics. Enzyme and Microbial Technology 2008; 43:252-256.
15	Messerschmıdt A, Huber R. The blue oxidases, ascorbate oxidase, laccase and ceruloplasmin modelling and structural relationships. Eur J Biochem 1990; 187:341-352. doi: 10.1111/j.1432-1033.1990.tb15311.x pmid: 2404764
16	Keles MS, Taysi S, Sen N, Aksoy H, Akcay F. Effect of corticosteroid therapy on serum and CSF malondialdehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci 2001; 28:141-143. pmid: 11383939
17	Güngör N, Ozyürek M, Güçlü K, Cekiç SD, Apak R. Comparative evaluation of antioxidant capacities of thiol-based antioxidants measured by different in vitro methods. Talanta 2011; 83:1650-1658. doi: 10.1016/j.talanta.2010.11.048 pmid: 21238764
18	Gur M, Aslan M, Yildiz A, Demirbag R, Yilmaz R, Selek S, et al. Paraoxonase and arylesterase activities in coronary artery disease. Eur J Clin Invest 2006; 36:779-787. doi: 10.1111/j.1365-2362.2006.01727.x pmid: 17032345
19	Haagen L, Brock A. A new automated method for phenotyping arylesterase (E.C.3.1.1.2.) based upon inhibition of enzymatic hydrolysis of 4-nitrophenyl acetate by phenyl acetate. Eur J Clin Chem Clim Biochem 1992; 30:391-395.
20	Erel O. Automated measurement of serum ferroxidase activity. Clin Chem 1998; 44:2313-2319. pmid: 9799759
21	Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82:70-77. pmid: 13650640
22	Hu ML, Louie S, Cross CE, Motchnik P, Halliwell B. Antioxidant protection against hyochlorous acid in human plasma. J Lab Clin Med 1993; 121:257-262. pmid: 8381845
23	Omaye ST. Metabolic modulation of carbon monoxide toxicity. Toxicology 2002; 180:139-150. pmid: 12324190
24	Halliwell B. Free Radicals in Biology and Medicine. Oxford: Oxford Science Publications, 2000.
25	Wang P, Zeng T, Zhang CL, Gao XC, Liu Z, Xie KQ, et al. Lipid peroxidation was involved in the memory impairment of carbon monoxide-induced delayed neuron damage. Neurochem Res 2009; 34:1293-1298. doi: 10.1007/s11064-008-9908-1 pmid: 19199032
26	Kavakli HS, Erel O, Delice O, Gormez G, Isikoglu S, Tanriverdi F. Oxidative stress increases in carbon monoxide poisoning patients. Hum Exp Toxicol 2011; 30:160-164. doi: 10.1177/0960327110388539
27	Fritz H, Kennedy D, Fergusson D, Fernandes R, Cooley K, Seely A, et al. Selenium and lung cancer: a systematic review and meta analysis. PLoS One 2011; 6:1-10.
28	Bhupathiraju SN, Tucker KL. Coronary heart disease prevention: nutrients, foods, and dietary patterns. Clin Chime Acta 2011; 412:1493-1514.
29	Talaulikar VS, Manyonda IT. Vitamin C as an antioxidant supplement in women's health: a myth in need of urgent burial. Eur J Obstet Gynecol Reprod Biol 2011; 157:10-13. doi: 10.1016/j.ejogrb.2011.03.017 pmid: 21507551

Parameters	Group 1 (n=107)	Group 2 (n=50)	P
Age (yr)	35.4±16.3	33.5±16.2	ns
BMI (kg/m²)	24.3±2.3	23.6±2.8	ns
Male/Female	50/57	24/26	ns
TG (mg/dL)	164.86±21.5	168.35±28.8	ns
TC (mg/dL)	169.89±39.3	172.56±34.4	ns
HDL C (mg/dL)	50.3±8.8	49.8±7.6	ns
LDL C (mg/dL)	128.44±23	125.94±20.4	ns

Parameters	Admission	90^th minute	180^th minute	P^*
COHb (%)	21.85±7.7	13.84±5.4	8.34±4.7	0.000
Paraoxonase (U/L)	143.34±51.8	147.52±57.90	148.02±61.38	0.484
Arylesterase (U/L)	108.32±16.16	113.52±19.76	124.64±26.81	0.000
Ceruloplasmin (U/L)	722.11±120	679.71±108	648.79±85.73	0.000
-SH (mmol/L)	0.40±0.06	0.41±0.07	0.41±0.06	0.154

Parameters	Groups	Admission	90^th minute	180^th minute	P
Paraoxonase (U/L)	Patient	143.34±51.8	147.52±57.90	148.02±61.38	0.001^*
	Control	187.04±31.7	—	—	0.000^#
					0.000^Δ
Arylesterase (U/L)	Patient	108.32±16.16	113.52±19.76	124.64±26.81	0.000
	Control	168.65±24.53	—	—	0.000
					0.000
Ceruloplasmin (U/L)	Patient	722.11±120	679.71±108	648.79±85.73	0.000
	Control	518.05±64.62	—	—	0.000
					0.000
-SH (mmol/L)	Patient	0.40±0.06	0.41±0.07	0.41±0.06	0.000
	Control	0.46±0.06	—	—	0.000
					0.000